A subsequent larger meta-analysis (including 16 trials consisting of 38,335 type 2 diabetics) found that SGLT2 inhibitors significantly reduced the combined endpoint of AF and atrial flutter (P  =  0.001) (99). The gene discussed is SLC5A2; the disease is atrial fibrillation.